20 Sep 2013 07:00
GW Pharmaceuticals to Present at the 2013 Aegis Capital Healthcare Conference
London, UK; 20 September 2013: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW") announced that Justin Gover, GW's Chief Executive Officer, is scheduled to present a general company update at the 2013 Aegis Capital Healthcare Conference in Las Vegas, NV on Friday, September 27, 2013, at 9:00 a.m. PT (12:00 p.m. ET).
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 22 countries. Sativex is also in Phase 3 clinical development as a potential treatment of pain in people with advanced cancer. This Phase 3 program is intended to support the submission of a New Drug Application for Sativex in cancer pain with the U.S. Food and Drug Administration and in other markets around the world. GW has established a world leading position in the development of plant-derived cannabinoid therapeutics and has a deep pipeline of additional cannabinoid product candidates, including two distinct compounds, GWP42004 and GWP42003, in Phase 2 clinical development for Type 2 diabetes and ulcerative colitis, respectively, and GWP42006 in Phase 1 clinical development for the treatment of epilepsy. For further information, please visit www.gwpharm.com.
Enquiries:
GW Pharmaceuticals plc | (Today) + 44 20 7831 3113 |
Justin Gover, Chief Executive Officer | (Thereafter) + 44 1980 557000 |
Stephen Schultz, VP Investor Relations (US) | 401 500 6570 |
|
|
FTI Consulting (Media Enquiries) |
|
Ben Atwell / Simon Conway / John Dineen (UK) | + 44 20 7831 3113 |
Robert Stanislaro (US) | 212 850 5657 |
|
|
Trout Group, LLC (US investor relations) |
|
Seth Lewis / Todd James | 646 378 2900 |
|
|